Key result
Vildagliptin 100 mg/day lowered HbA1c compared with placebo (WMD -0.77%; 95% CI -0.96 to -0.58) and was non-inferior to thiazolidinediones, sulfonylureas and α-glycosidase inhibitors.
Why the study?
Does vildagliptin improve HbA1c in patients with type 2 diabetes?
Population
Patients with type 2 diabetes (T2DM) from 30 randomized controlled trials
Comparison
Vildagliptin (50 mg/day or 100 mg/day) vs Placebo or other hypoglycaemic agents
Design
Meta-analysis
Authors
Loading...
Supports vildagliptin for glycemic control in type 2 diabetes; reinforces its non-inferiority to established oral agents.
Meta-Analysis
Does vildagliptin improve HbA1c in patients with type 2 diabetes?
Mean Difference: -0.77 (95% CI -0.96–-0.58)
Vildagliptin is effective for glycemic control in type 2 diabetes with a low risk of hypoglycemia and other adverse reactions.
Cai et al. (2011) conducted a meta-analysis in Type 2 diabetes. Vildagliptin vs. Placebo or other hypoglycaemic agents was evaluated on HbA1c (WMD -0.77%, 95% CI -0.96 to -0.58). Vildagliptin 100 mg/day lowered HbA1c compared with placebo (WMD -0.77%; 95% CI -0.96 to -0.58) and was non-inferior to thiazolidinediones, sulfonylureas and α-glycosidase inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: